In both IHC assays, the percentage of tumors with PD-L1 expression on ≥1%, ≥5% and ≥50% of tumor cells was similar in groups of patients with and without EGFR gene mutations (Table 3 and 4). This evidence concerns the gene EGFR and neoplasm.